StockData
Upstream Bio, Inc. logo

Upstream Bio, Inc. (UPB) shareholders

UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.10−0.05 (-2.33%)

Close on Nov 17, 2026Market cap $115.02MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
92.3%
51M of 55M shares
Institutional holders
149
38 new, 28 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 15 sales
Net sold $104.80K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (14.80%)
7,936,88014.80%13G (passive) amendmentJun 30, 2025
Len Blavatnik
Joint filing with AI Upstream LLC (10.70%), Access Industries Holdings LLC (10.70%) and 2 more
5,494,41010.70%13D (active)Oct 15, 2024
OrbiMed Capital GP VIII LLC
Joint filing with OrbiMed Advisors LLC (8.90%)
4,554,8738.90%13D (active)Oct 15, 2024
Norges Bank4,206,5867.73%13G (passive) amendmentJun 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (6.90%)
3,793,9556.90%13G (passive) amendmentOct 30, 2026
Xiangmin Cui
Joint filing with Decheng Capital Global Life Sciences Fund IV, L.P. (5.80%), Decheng Capital Management IV (Cayman), LLC (5.80%)
3,285,2936.10%13G (passive)Dec 31, 2024
BlackRock, Inc.2,814,7145.20%13G (passive)Jun 30, 2026
TCG Crossover Fund I, L.P.
Joint filing with TCG Crossover GP I, LLC (5.20%), Chen Yu (5.20%)
2,801,7635.20%13G (passive)Dec 31, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of UPBValueChange% of portfolio
FMR LLC8,162,89714.90%$56.49M+61,3340.00%
Orbimed Advisors LLC5,693,58910.40%$39.40M–0.73%
Norges Bank3,768,6196.88%$26.08MNew0.00%
BlackRock, Inc.3,753,3586.85%$25.97M+382,6690.00%
Decheng Capital LLC2,724,8684.98%$18.86M–2.58%
Enavate Sciences Gp, LLC2,459,7034.49%$17.02M–4.93%
Vanguard Capital Management LLC1,876,7343.43%$12.99M+3,1600.00%
Millennium Management LLC1,143,7752.09%$7.91M+206,4520.00%
D. E. Shaw & Co., Inc.1,036,0441.89%$7.17M+215,5640.00%
JPMorgan Chase & Co1,012,0441.85%$7.01M+549,0430.00%
Qube Research & Technologies Ltd978,5001.79%$6.77M+359,1790.01%
Parkman Healthcare Partners LLC935,2471.71%$6.47M+148,4640.66%
Geode Capital Management, LLC931,2611.70%$6.45M−19,3560.00%
SEB Asset Management AB878,4731.60%$6.08M–0.02%
Woodline Partners LP831,4811.52%$5.75M–0.02%
State Street Corp766,3231.40%$5.30M+60,9730.00%
Vanguard Portfolio Management LLC712,6671.30%$4.93M−15,0440.00%
Y-Intercept (Hong Kong) Ltd693,5551.27%$4.80M−307,0760.09%
Bain Capital Life Sciences Investors, LLC600,9491.10%$4.16M−266,2620.25%
Aqr Capital Management LLC544,8690.99%$3.77M+472,6980.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202614951M92.3%38 / 6528 / 2811M5M
Q1 202614045M82.0%47 / 4735 / 3813M17M
Q4 202513351M93.4%46 / 4233 / 812M5M
Q3 20259544M81.2%22 / 3822 / 104M8M
Q2 20258348M88.3%14 / 4113 / 105M3M
Q1 20257946M84.5%24 / 1126 / 146M1M
Q4 20247042M76.8%70 / 00 / 042M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

147 funds held UPB in Q2 2026, 30% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of UPBValue% of fundAs of
Vanguard Total Stock Market Index Fund1,443,0252.63%$9.99M0.00%Jun 30, 2026
Fidelity Small Cap Growth Fund1,371,3722.50%$8.65M0.10%Jul 31, 2026
Fidelity Stock Selector Small Cap Fund1,321,8002.41%$8.34M0.11%Jul 31, 2026
Fidelity Series Small Cap Opportunities Fund965,8001.76%$6.09M0.13%Jul 31, 2026
iShares Russell 2000 ETF921,0631.68%$6.37M0.01%Jun 30, 2026
Select Health Care Portfolio800,0001.46%$6.69M0.12%May 31, 2026
Fidelity Small Cap Growth K6 Fund693,6181.27%$4.38M0.10%Jul 31, 2026
Fidelity Advisor Biotechnology Fund691,0031.26%$4.36M0.20%Jul 31, 2026
Fidelity Advisor Health Care Fund400,0000.73%$2.52M0.08%Jul 31, 2026
Vanguard Extended Market Index Fund386,8770.71%$2.68M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund384,5090.70%$2.43M0.01%Jul 31, 2026
BlackRock Health Sciences Opportunities Portfolio341,6750.62%$2.86M0.05%May 29, 2026
iShares Russell 2000 Value ETF338,2610.62%$2.34M0.02%Jun 30, 2026
iShares Biotechnology ETF256,1300.47%$1.77M0.02%Jun 30, 2026
Select Biotechnology Portfolio234,6570.43%$1.96M0.04%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Everett Rand SutherlandChief Executive Officer, Director68,7170.13%Sep 17, 2026
Aaron DeykinChief Medical Officer32,3020.06%Sep 17, 2026
Allison AmbroseGeneral Counsel15,5630.03%Sep 17, 2026
Michael GrayCFO and COO27,9420.05%Sep 17, 2026
Adam HoughtonChief Business Officer22,9010.04%Sep 17, 2026
Erez ChimovitsDirector4,554,8738.32%Jun 11, 2026
Harold Edward FlemingDirector––Jun 11, 2026
Liam RatcliffeDirector––Jun 11, 2026
Marcella K. RuddyDirector––Jun 11, 2026
Ronald C. Renaud JRDirector––Jun 11, 2026
Daniella BeckmanDirector––Jun 11, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Adam Houghton
Chief Business Officer
Sep 16, 2026Sale−700$5.49$3.84K22,901
Michael Gray
CFO and COO
Sep 16, 2026Sale−853$5.49$4.68K27,942
Allison Ambrose
General Counsel
Sep 16, 2026Sale−485$5.49$2.66K15,563
Aaron Deykin
Chief Medical Officer
Sep 16, 2026Sale−895$5.49$4.91K32,302
Everett Rand Sutherland
Chief Executive Officer, Director
Sep 16, 2026Sale−2,095$5.49$11.50K68,717
Michael Gray
CFO and COO
Jun 16, 2026Sale−853$6.10$5.20K28,795
Aaron Deykin
Chief Medical Officer
Jun 16, 2026Sale−895$6.10$5.46K33,197
Allison Ambrose
General Counsel
Jun 16, 2026Sale−477$6.10$2.91K16,048
Adam Houghton
Chief Business Officer
Jun 16, 2026Sale−700$6.10$4.27K23,601
Everett Rand Sutherland
Chief Executive Officer, Director
Jun 16, 2026Sale−2,095$6.10$12.78K70,812
Everett Rand Sutherland
Chief Executive Officer, Director
Mar 16, 2026Sale−2,093$9.29$19.44K72,907
Aaron Deykin
Chief Medical Officer
Mar 16, 2026Sale−894$9.29$8.31K32,687
Michael Gray
CFO and COO
Mar 16, 2026Sale−852$9.29$7.92K29,648
Adam Houghton
Chief Business Officer
Mar 16, 2026Sale−699$9.29$6.49K24,301
Allison Ambrose
General Counsel
Mar 16, 2026Sale−475$9.29$4.41K16,525
Everett Rand Sutherland
Chief Executive Officer, Director
Jan 2, 2026Award+75,000––75,000
Allison Ambrose
General Counsel
Jan 2, 2026Award+17,000––17,000
Adam Houghton
Chief Business Officer
Jan 2, 2026Award+25,000––25,000
Michael Gray
CFO and COO
Jan 2, 2026Award+30,500––30,500
Aaron Deykin
Chief Medical Officer
Jan 2, 2026Award+32,000––33,581
Erez Chimovits
Director, 10% owner
Oct 15, 2024Buy+660,000$17.00$11.22M4,554,873
Erez Chimovits
Director, 10% owner
Oct 15, 2024Conversion+2,887,833––3,894,873
Erez Chimovits
Director, 10% owner
Oct 15, 2024Buy+165,000$17.00$2.81M1,138,716
Erez Chimovits
Director, 10% owner
Oct 15, 2024Conversion+721,956––973,716
Industries Holdings LLC Access
10% owner
Oct 15, 2024Conversion+1,172,410––5,494,410
Industries Holdings LLC Access
10% owner
Oct 15, 2024Conversion+3,147,000––4,322,000
Industries Holdings LLC Access
10% owner
Oct 15, 2024Buy+1,175,000$17.00$19.98M1,175,000
Advisors Llc Orbimed
Director, 10% owner
Oct 15, 2024Buy+660,000$17.00$11.22M4,554,873
Advisors Llc Orbimed
Director, 10% owner
Oct 15, 2024Conversion+721,956––973,716
Advisors Llc Orbimed
Director, 10% owner
Oct 15, 2024Buy+165,000$17.00$2.81M1,138,716
Advisors Llc Orbimed
Director, 10% owner
Oct 15, 2024Conversion+2,887,833––3,894,873
Biomedical Innovation Master Investors (Cayman) II L.P. Wellington
10% owner
Oct 15, 2024Conversion+894,733––894,733

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
7.09%
4M shares short
Days to cover
2.7
At 1M shares a day
Change since last report
-20.8%
From 4M shares
Short volume, 20 days
17.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Upstream Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,112 shares on Oct 5, 2026 over the last 90 days.

See a number that looks wrong?